Hypertriglyceridemia and Cardiovascular Diseases: Revisited
Open Access
- 1 January 2016
- journal article
- review article
- Published by The Korean Society of Cardiology in Korean Circulation Journal
- Vol. 46 (2), 135-144
- https://doi.org/10.4070/kcj.2016.46.2.135
Abstract
Residual cardiovascular risk and failure of high density lipoprotein cholesterol raising treatment have refocused interest on targeting hypertriglyceridemia. Hypertriglyceridemia, triglyceride-rich lipoproteins, and remnant cholesterol have demonstrated to be important risk factors for cardiovascular disease; this has been demonstrated in experimental, genetic, and epidemiological studies. Fibrates can reduce cardiovascular event rates with or without statins. High dose omega-3 fatty acids continue to be evaluated and new specialized targeting treatment modulating triglyceride pathways, such as inhibition of apolipoprotein C-III and angiopoietin-like proteins, are being tested with regard to their effects on lipid profiles and cardiovascular outcomes. In this review, we will discuss the role of hypertriglyceridemia, triglyceride-rich lipoproteins and remnant cholesterol on cardiovascular disease, and the potential implications for treatment stargeting hypertriglyceridemia.Keywords
This publication has 91 references indexed in Scilit:
- The VITamin D and OmegA-3 TriaL (VITAL): Rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular diseaseContemporary Clinical Trials, 2012
- n–3 Fatty Acids and Cardiovascular Events after Myocardial InfarctionThe New England Journal of Medicine, 2010
- Biological, clinical and population relevance of 95 loci for blood lipidsNature, 2010
- Excess of rare variants in genes identified by genome-wide association study of hypertriglyceridemiaNature Genetics, 2010
- Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysisThe Lancet, 2010
- Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studiesThe Lancet, 2010
- Effects of Combination Lipid Therapy in Type 2 Diabetes MellitusThe New England Journal of Medicine, 2010
- Major Lipids, Apolipoproteins, and Risk of Vascular DiseaseJama-Journal Of The American Medical Association, 2009
- Fasting Compared With Nonfasting Triglycerides and Risk of Cardiovascular Events in WomenJama-Journal Of The American Medical Association, 2007
- Nonfasting Triglycerides and Risk of Myocardial Infarction, Ischemic Heart Disease, and Death in Men and WomenJama-Journal Of The American Medical Association, 2007